Trospium Chloride Tablet, Film Coated
Product Images NDC 76282-336

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 76282-336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

This is a graph that shows the plasma concentration (measured in ng/mL) of a substance over time (measured in hours post-dose). The x-axis shows the time post-dose ranging from 0 to 48 hours, and the y-axis shows the plasma concentration ranging from 0 to 50 ng/mL.*

FDA Label Image

Structure (Trospium 01)

FDA Label Image

Trospium-chloride-20mg (Trospium Chloride 20mg)

Exelan Trospium Chloride Tablets, USP 20mg is a prescription medication used to treat overactive bladder symptoms such as urinary incontinence, urgency, and frequency. Each package contains 60 film-coated tablets that should be stored at 20°to 25° 68° to 77°F. Patients must follow the instructions on the Patient Information Leaflet provided separately by the pharmacist. Exelan Trospium Chloride Tablets should be kept in a tight container and away from children. It is manufactured by InvaGen Pharmaceuticals, a subsidiary of Cipla Ltd, and distributed by Exelan Pharmaceuticals, Inc. in Boca Raton, FL. For complete prescribing information, read the package insert.*

FDA Label Image

Figure2 (Trospium Fig2)

Figure 2 shows the Mean Change from Baseline in Urinary Frequency/24 Hours, by Visit for Study 1. The data includes a placebo group of 256 participants and a Trospium Chloride group of 253 participants. The week of treatment is displayed along the bottom axis, with the y-axis indicating the mean change in urinary frequency. Statistical significance is denoted by p-values displayed above the bars.*

FDA Label Image

Figure3 (Trospium Fig3)

The text describes a figure titled "Figure 3," which shows the mean change from baseline in urge incontinence per week in Study 1. The figure compares results between a placebo group and a group taking Trospium Chloride (N=253). The figure shows the mean (+SE) change at different weeks of treatment. There is a significant decrease in urge incontinence in the Trospium Chloride group at week 16 (p=0.003) and week 48 (p=0.012).*

FDA Label Image

Fig4 (Trospium Fig4)

This is a figure showing the change from baseline in urinary frequency per 24 hours for Study 2. The x-axis represents the week of treatment, while the y-axis shows the mean change with standard error bars. The study included 326 participants on placebo and 323 participants on Sanctura®. There is no additional information available.*

FDA Label Image

Figure5 (Trospium Fig5)

The graph in Figure 5 shows the mean change from baseline in urge incontinence per week over the course of treatment for Study 2. The study includes a placebo group with 325 participants and a group receiving Sanctura with 323 participants. It appears that there is a significant mean improvement in urge incontinence for the Sanctura group compared to the placebo group starting around week 2 of treatment.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.